Sonic Healthcare Stock (OTC:SKHHY), Trade Ideas

Sonic Healthcare

Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the U.K., the second largest in Belgium and New Zealand, and the third largest in the U.S. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the U.S., and 35% in Europe.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACMR

ACRE

ADBE

ADSK

ADYEY

AEIS

AGNC

AHCO

ALMFF

AMAT

AMWD

ANCUF

ANSS

APLS

APPF

ARMK

ASHTF

ASHTY

ATKR

ATLC

ATRC

ATVI

AUCOY

AUDC

BF-B

BMCH

BMDPF

BOWFF

BWAY

CACI

CCLAY

CCOI

CCWOF

CDPYF

CELH

CHJI

CHNG

CLZNY

COST

CPPSF

CPRT

CPWHF

CRAI

CROMF

CSGP

CSII

CSLLY

CTXS

CVCO

DASTY

DBOEY

DIOD

DNNGY

DOGEF

DOTDF

Stocks That Hit 52-Week Highs On Wednesday

AAPL

ACDVF

ACGL

ACIA

ADDYY

ADUS

ADYYF

AFGC

AKAM

AMADY

AMRC

APTO

ARDC

ASMIY

ASMVY

ATEYY

BABA

BAYRY

BAGGER DAVE'S BURGER TAV by Bagger Dave's Burger Tavern, Inc.

BDVB

BKNG

BLDP

BRKR

BYCBF

BYDIF

CABO

CARCY

CCNTF

CCOEY

CDAY

CDDRF

CFFA

CFRX

CIGI

CLNXF

CNVVY

COLL

COPJF

COUP

CRBJY

CROX

CSIOF

CSWI

CSXXY

CTAC

CUEN

DEAC

DERM

DRTGF

DXCM

DYFSF

ECNCF

Stocks That Hit 52-Week Highs On Friday

AANNF

ABVN

ACIW

ACLS

ADDDF

AEBZY

AFGVY

AGTC

AHEXY

AILQF

AKRFF

AMED

ANPDF

APAM

APLT

ARCAY

ARES

ARGX

ARVN

ASML

ATGN

ATZAF

AZIHF

BILI

BIOS

BIRMF

BKOR

BPOP

BRK-A

BRK-B

BTAFF

CAMT

CASH

AllianzGI Convertible & Income 2024 Target Term Fund Common Shares of Beneficial Interest

CDLX

CGEN

CHGCY

CHRYY

CLGN

CMXHF

CNNE

COHR

COHU

Stocks That Hit 52-Week Highs On Thursday

SONIC HEALTHCARE SP/ADR by Sonic Healthcare Ltd.

Sonic Healthcare Ltd

Citigroup analyst Atif Malik maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Neutral and lowers the price target from $137 to $120.

Price Target

Analyst Ratings

SLAB

Citigroup Maintains Neutral on Silicon Laboratories, Lowers Price Target to $120

In a compelling showcase of how sports figures leverage their platforms beyond the field, former NFL athletes <a href="https://www.benzinga.com/general/sports/24/04/38358885/joique-bell-to-discuss-journey-from-rookie-to-prominent-nfl-running-back-at-benzinga-draft-event">Joique Bell</a> and<a href="https://www.benzinga.com/markets/cannabis/24/03/37797148/former-nfl-legends-bring-top-cannabis-strains-to-boston-with-launch-of-primitiv"> Rob Sims</a> shared their philanthropic journeys today (April 25) during the <a href="https://www.youtube.com/watch?v=93htkUYdGNc">Benzinga Sports Business Titans Draft</a> event in Detroit. 
The panel, adjacent to the NFL Draft at Campus Martius, highlighted the transformative impact athletes can have in their communities post-retirement.
<h1 class="wp-block-heading">Athletes Turned Philanthropists</h1>
Moderated by Rachel Decker, president of Detroit Philanthropy, the conversation delved into the personal motivations behind the athletes&#8217; commitments to giving back. 
Bell, a Michigan native and former Detroit Lion, emphasized the influence of his upbringing on his charitable efforts. 
&#8220;Growing up, being involved in community service was ingrained in me by my parents,&#8221; Bell said. He discussed his focus on literacy and education through his foundation, which aims to improve reading levels among students within a short period significantly.
Sims, who transitioned from the gridiron to various business and charitable endeavors, highlighted his strategic approach to philanthropy. 
&#8220;It&#8217;s about making an impact with the resources we have, ensuring our efforts genuinely help those in need,&#8221; Sims stated. His involvement with local organizations such as Detroit PAL and the Children&#8217;s Center demonstrates his commitment to youth and community health.
<h1 class="wp-block-heading">Impact And Influence&nbsp;</h1>
The discussion also covered the athletes&#8217; strategies for selecting and managing philanthropic engagements. 
Both Bell and Sims stressed the importance of aligning with causes that reflect their values and where they can make a meaningful difference. Bell shared his rigorous approach to vetting organizations before partnering with them, ensuring alignment with his goals to support community development.
<h1 class="wp-block-heading">Advice For The Next Generation&nbsp;</h1>
As the event drew the attention of young athletes and aspiring philanthropists, Bell and Sims offered advice on starting and running charitable foundations. 
&#8220;Understand the work that goes into managing a foundation; it&#8217;s akin to running a business,&#8221; Sims advised. Bell echoed this sentiment, emphasizing the importance of commitment and genuine passion for the cause.
<h1 class="wp-block-heading">Legacy Beyond The Field&nbsp;</h1>
Reflecting on their legacies, both athletes expressed a desire to be remembered for their contributions off the field as much as their achievements on it. 
&#8220;It&#8217;s not just about the sports; it&#8217;s about using our platform to make a lasting impact,&#8221; said Bell.
Photo by Dustin Blitchok.

Sports

Events

Game Changers: Ex-NFL Players Talk Philanthropy For Today And Next-Gen At Benzinga Titans Draft Event

Citigroup analyst Ronald Josey maintains Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) with a Neutral and lowers the price target from $320 to $280.

Citigroup Maintains Neutral on Lithia Motors, Lowers Price Target to $280

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $94 to $91.

BMRN

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $91

Citigroup analyst Michelle Fang maintains New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) with a Buy and raises the price target from $66 to $127.

New Oriental Education & Technology Group

Citigroup Maintains Buy on New Oriental Education, Raises Price Target to $127

Citigroup analyst Andrew Kaplowitz maintains Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) with a Buy and lowers the price target from $101 to $98.

Citigroup Maintains Buy on Fortive, Lowers Price Target to $98

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Guidance

MSFT

Microsoft Sees FY24 Productivity And Business Processes Revenue $19.9B-$20.2B; Intelligent Cloud Revenue $28.4B-$28.7B; More Personal Computing Revenue $15.2B-$15.6B; Cost Of Revenue COGS Of $19.6B-$19.8B; Operating Expenses Of $17.15B-$17.25B; Effective Tax Rate ~18%

Citigroup analyst Anthony Pettinari maintains Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) with a Neutral and lowers the price target from $183 to $181.

Citigroup Maintains Neutral on Packaging Corp of America, Lowers Price Target to $181

Citigroup analyst Christopher Allen maintains Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) with a Buy and raises the price target from $22.5 to $24.5.

VIRT

Citigroup Maintains Buy on Virtu Finl, Raises Price Target to $24.5

Citigroup analyst Thomas Palmer maintains Bunge Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) with a Buy and raises the price target from $117 to $122.

Citigroup Maintains Buy on Bunge Global, Raises Price Target to $122

Citigroup analyst Fatima Boolani maintains Fastly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) with a Neutral and lowers the price target from $20 to $15.

FSLY

Citigroup Maintains Neutral on Fastly, Lowers Price Target to $15

Citigroup analyst Fatima Boolani maintains Akamai Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) with a Neutral and lowers the price target from $140 to $117.

Citigroup Maintains Neutral on Akamai Techs, Lowers Price Target to $117

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and raises the price target from $79 to $85.

Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $85